PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET ANALYSIS

Porcine Reproductive and Respiratory Syndrome Vaccine Market, By Product Type (Modified Live Virus Vaccine, Inactivated Vaccine, and Subunit Vaccines), By Route of Administration (Intramuscular and Intradermal), By Virus Genotype (Type I and Type II), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlooks, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI3285
Formats :
Excel and PDF
Industry : Biotechnology

Regional Analysis

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market - Regional Insights

North America accounted for the largest market share in 2018 owing to launch and approval of new vaccines for the porcine reproductive and respiratory syndrome in the region. For instance, in June 2018, Elanco Animal Health, a division of Eli Lily and Company, introduced a modified live respiratory vaccine, Prevacent PRRS to reduce the porcine reproductive and respiratory syndrome (PRRS), respiratory form, in two weeks or older piglets. Similarly, in 2018, MSD Animal Health launched a needle free device, IDAL 3G, with two injector heads for intradermal vaccination. The device makes the vaccine administration a safer and less stressful procedure for the pigs and more efficient and convenient for farmers. The device is used to administer vaccines like PORCILIS PRRS, for porcine reproductive and respiratory syndrome virus and PORCILIS PCV ID, for porcine circovirus type 2 simultaneously.